Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000333 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Benztropine for Cocaine Craving - 2

A Phase 2 study of Cocaine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 2
Development phase
1
Study location

NCT00000333 is a Phase 2 study of Cocaine-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000333, a Phase 2 study of Cocaine-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 2
Development phase
1
Study location

Study Summary

The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.

Conditions Studied

Interventions

  • DRUG Benztropine

Study Locations (1)

District of Columbia

  • Washington DC VA - Washington D.C.

Trial Details

FieldValue
Start Date 2001-05
Est. Completion 2003-04
Phase Phase 2

What the Registry Record Tells You About NCT00000333

The ClinicalTrials.gov registry entry for NCT00000333 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Benztropine is the first listed.

NCT00000333 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00000333 about?

NCT00000333 is a clinical study titled "Evaluation of Benztropine for Cocaine Craving - 2". The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.

What is the current status of trial NCT00000333?

This trial is currently completed. It is a Phase 2 study. The study started on 2001-05. Estimated completion is 2003-04.

What conditions does trial NCT00000333 study?

This clinical trial studies the following conditions: Cocaine-Related Disorders.

What interventions are being tested in trial NCT00000333?

The interventions under investigation include: Benztropine (DRUG).

Who is sponsoring clinical trial NCT00000333?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000333 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.